Genetic Testing Decision Aid for Ovarian and Pancreatic Cancer
This study is testing two ways to help people with ovarian or pancreatic cancer understand genetic testing. You would either use an electronic decision aid (a computer program to help you make choices) or receive pre-test genetic counseling (talking with a genetic expert). The study wants to see which method helps you learn more, feel more confident in your decisions, and participate more in shared decision-making with your doctor. To join, you must be 18 or older, be seen at Massachusetts General Hospital or Boston Medical Center, and have been diagnosed with malignant epithelial ovarian carcinoma (a type of ovarian cancer) or malignant pancreatic adenocarcinoma (a type of pancreatic cancer). The study is currently recruiting about 350 people.
- Study design
- This is a randomized interventional study, meaning participants will be assigned by chance to one of two groups. About 350 people are expected to participate.
- What's involved
- You would complete surveys and questionnaires in conjunction with either a genetic counselor visit or using the electronic decision aid. The study procedures will last up to 2 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your knowledge, decisional conflict, and shared decision-making will be measured at 1 week after your genetics session, which is approximately 2 weeks after baseline.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Genetic Testing Decision Aid
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Daniel C. Chung, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Average change in knowledge survey scorebaseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks
Average change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.
- Decisional Conflict Scores1 week after genetics session
The decisional conflict score is a score ranging from 0-100 that is measured from a 10-question validated decisional conflict scale. The scale assesses participant's confidence in their decision with higher scores indicating higher decisional conflict.
- Shared Decision Making Process Scores1 week after genetics session
The shared decision making process score is a score on a scale of 1-4 based on responses on a validated 4-item shared-decision making scale. The scale assesses how well the decision aid/oncology provider, or the genetic counselor engaged in shared decision-making as perceived by the subject. Higher scores on this scale indicate more shared decision making.